Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Lenalidomide (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 23 Jul 2015 Primary endpoints been amended.
- 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov reccord.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History